ISPOR Establishes New “Women in Health Economics and Outcomes Research” Initiative

Published Nov 7, 2017
Glasgow, Scotland, UK—7 November 2017—ISPOR, the professional society for health economics and outcomes research (HEOR), held an open meeting this afternoon that was designed to gain member feedback on a new initiative, “ISPOR Women in HEOR/Science.” The open meeting was held today at ISPOR’s 20th Annual European Congress in Glasgow, Scotland, UK. The session was led by ISPOR President Shelby D. Reed, PhD, RPh, Duke University, Durham, NC, USA and Olivia Wu, PhD, University of Glasgow, Glasgow, UK. The open meeting also featured a presentation by guest speaker, Lizzie Massey, senior vice president, marketing products with Synchrony Financial. The proposed vision for the ISPOR Women in HEOR initiative is to:
  • Support the growth, development, and contribution of women in HEOR
  • Serve as a catalyst for women’s leadership in the field
  • Offer a platform for ISPOR women to collaborate, network, share, and mentor each other
Drs. Reed and Wu emphasized that all efforts to improve diversity are not just the “right thing to do.” Research evidence shows that diversity is, in fact, good for business. The speakers reviewed a number of studies that consistently demonstrate that organizations with diverse leadership teams perform significantly better than those that lack diversity. Yet still women account for less than one-third of those employed in scientific research and development. Research also shows that women in the science, technology, engineering, and mathematics (STEM) fields earn less than their male counterparts (83% of men’s earnings in the United States). Even when women are successful in the STEM fields, recent studies illustrate what is referred to as a “leaky pipeline,” where the number of women decreases significantly as the level of the position increases (with 32% of women in entry-level faculty positions and only 11% in senior-level faculty positions). The open meeting solicited member input from the audience on a number of key issues that will inform development of this initiative. Individuals interested in contributing to the ISPOR Women in HEOR initiative can complete the online form. Additional information on the ISPOR 20th Annual European Congress can be found here. Released presentations from the congress can be found here. Interested parties can follow news and developments from the congress on social media using the hashtag #ISPORGlasgow. ###   ABOUT ISPOR ISPOR, the professional society for health economics and outcomes research (HEOR), is an international, multistakeholder, nonprofit dedicated to advancing HEOR excellence to improve decision making for health globally. The Society is the leading source for scientific conferences, peer-reviewed and MEDLINE-indexed publications, good practices guidance, education, collaboration, and tools/resources in the field. Web: www.ispor.org | LinkedIn: http://bit.ly/ISPOR-LIn | Twitter: http://bit.ly/ISPOR-T (@ISPORorg) | YouTube: http://bit.ly/ISPOR-YT | Facebook: http://bit.ly/ISPOR-FB      

Related Stories

Landmark Analysis in Value in Health Uncovers Potential Research Efficiency Gains

Sep 15, 2025

Value in Health, the official journal of ISPOR announced the publication of a landmark scoping review that provides a comprehensive mapping of patient preference studies across key medical domains, revealing the first robust evidence base for advancing meta-analyses and benefit transfer methods in healthcare decision-making.

ISPOR Real-World Evidence Summit 28-30 September 2025 | Tokyo, Japan

Sep 9, 2025

ISPOR announced details for its ISPOR Real-World Evidence Summit 2025: Through The Lens of Asia Pacific. The Summit brings together top experts, decision makers, and industry leaders to explore the latest breakthroughs, share cutting-edge research, and discuss innovative solutions to the region’s most pressing healthcare challenges.

"Most-Favored Nation" Drug Pricing Strategy May Backfire, New Research Warns

Sep 3, 2025

Value in Health, the official journal of ISPOR announced the publication of a new analysis suggesting that the Trump Administration's "Most-Favored Nation" approach to lowering US drug prices by referencing international prices may not achieve its intended goals, based on decades of experience with similar policies in Europe.
Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now

×